1. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy
   HAIJIAO JIANG et al, 2015 CrossRef
2. PEGylated Graphene Oxide-Mediated Protein Delivery for Cell Function Regulation
   He Shen et al, 2012, ACS Appl. Mater. Interfaces CrossRef
3. Customizing chemotherapy in thoracic malignancies based on ERCC1 expression
   Jens Benn Sørensen et al, 2013, Lung Cancer Management CrossRef
4. ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy
   Ozer Ozdemir et al, 2013, Asian Pacific Journal of Cancer Prevention CrossRef
5. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer
   Qiang Zhang et al, 2014, Cancer Chemother Pharmacol CrossRef
6. ERCC1 Single Nucleotide Polymorphism C8092A, but Not Its Expression Is Associated with Survival of Esophageal Squamous Cell Carcinoma Patients from Fujian Province, China
   Wan-Hua Chen et al, 2014, PLoS ONE CrossRef
7. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer
   Elfriede Bollschweiler et al, 2016, Annals of Surgery CrossRef